Search clinical trials for: NGX267

Total 7 results

NextPoint Therapeutics, Inc.

Recruiting

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2

Metastatic Malignant Neoplasm

United States
TorreyPines Therapeutics

Completed

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

Sjogren's Syndrome | Xerostomia

United States
TorreyPines Therapeutics

Completed

A Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Voluneteers

Healthy | Hyperalgesia

United States
Genzyme, a Sanofi Company

Terminated

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

Diarrhea | Enterocolitis, Pseudomembranous | Clostridium Difficile

United States
Genzyme, a Sanofi Company

Completed

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

Clostridium Enterocolitis | Pseudomembranous Colitis

United States, Canada, Puerto Rico
Genzyme, a Sanofi Company

Completed

A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea

Antibiotic-Associated Diarrhea | Pseudomembranous Colitis | Clostridium Difficile Diarrhea

Canada
Genzyme, a Sanofi Company

Completed

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea

Diarrhea | Clostridium Enterocolitis

Australia, Belgium, France, Spain, Germany, Portugal, Switzerland, Austria, United Kingdom, Ireland, Czech Republic, Denmark, Norway, Sweden

Search clinical trials for: NGX267

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations